Ariana Pelosci

Between 2004 to 2016, investigators reported that mammography rates decreased among breast cancer survivors.

Data regarding different dosing strategies of elimusertib for advanced solid tumors with ATM alterations and other DNA damage repair gene defects display early efficacy of the therapy.

Based on results from the EPIK-P1 trial, the FDA has granted accelerated approval to alpelisib for PIK3CA-related overgrowth spectrum.

Longer and more durable remissions were identified with the addition of CART-19 to ibrutinib for patients with chronic lymphocytic leukemia.

Investigators spoke to the disparities that are present in multiple myeloma and possible causes such as socioeconomic factors.

Based on results from a phase 1 trial, the FDA has granted fast track designation to PRGN-3006 UltraCAR-Tin relapsed/refractory acute myeloid leukemia.

A biologics license application for omburtamab was resubmitted following a refusal to file letter in 2020 for pediatric patients with central nervous system/leptomeningeal metastatic from neuroblastoma.

Pediatric patients with high allelic ratio FLT3/ITD–positive acute myeloid leukemia may benefit from treatment with sorafenib plus chemotherapy.

Patients with EGFR-mutated non–small cell lung cancer had an improved survival benefit following treatment with a first-line tyrosine kinase inhibitors plus up-front local radiotherapy.

Patients with human papillomavirus–associated oropharyngeal carcinoma who were given de-escalated doses of radiotherapy saw a better quality of life and favorable outcomes.

The addition of relacorilant to nab-paclitaxel has improved overall survival in patients with recurrent, platinum-resistant ovarian cancer.

Phillip S. Low, PhD, pioneered development of 177Lu-PSMA-617 for patients with metastatic castration-resistant prostate cancer and spoke about its recent approval.

A significant improvement in progression-free survival was observed in the phase 3 ATHENA-MONO trial with first-line maintenance rucaparib vs placebo in patients with advanced ovarian cancer.

Jun J. Mao, MD, MSCE, reviews how traditional, complementary, and integrative medicine can assist clinicians to better treat patients with cancer all over the world.

A new drug application for futibatinib has been accepted for priority review in patients with previously treated locally advanced or metastatic cholangiocarcinoma with FGFR2 gene rearrangements.

Patients with cancer are at a higher risk for adverse financial effects compared with those who have not been diagnosed.

While quality of life did not improve with esophageal-sparing intensity-modulated radiotherapy, patients with stage III/IV non–small cell lung cancer did experience a reduction in symptomatic esophagitis.

A biologics license application for mirvetuximab soravtansine, which demonstrated a clinically meaningful objective response rate, was submitted to the FDA for folate receptor α-high platinum-resistant ovarian cancer that has previously been treated with 1 to 3 lines of systemic treatments.

The FDA supported submission of application for approval of zandelisib in follicular lymphoma and other indolent non-Hodgkin lymphomas based on the phase 3 COASTAL trial.

Patients with prostate cancer who received surgery had the highest rate of treatment-related regret followed by radiotherapy and active surveillance.

Patients with clinically lymph node–positive breast cancer who achieved cN0 disease following treatment neoadjuvant chemotherapy with 3 or more negative sentinel lymphoma nodes identified by sentinel lymphoma node biopsy alone had a decrease in nodal recurrence.

Gennady Bratslavsky, MD, spoke about the evolution for treatments in renal cell carcinoma and how surgery may play a role.

The 6.5-year updated analysis of the phase 3 CheckMate 067 trial highlighted notable overall survival benefit with nivolumab alone or in combination with ipilimumab for patients with advanced melanoma.

Pembrolizumab has been approved by the FDA for the use in advanced microsatellite instability–high/mismatch repair–deficient endometrial cancer following prior systemic therapy.

7HP340 was granted fast track designation in combination with an anti–CTLA-4 treatment by the FDA for patients with unresectable or malignant melanoma for whom PD-1 inhibition therapy has failed.

The phase 3 PRIME study showed increased progression-free survival for patients with newly diagnosed ovarian cancer who were treated with an individualized starting dose of maintenance niraparib vs placebo.

The FoundationOne CDx diagnostic was approved as a companion diagnostic to help identify EGFR 19 deletions or exon 21 alterations in non–small cell lung cancer.

Patients with recurrent ovarian cancer experienced a longer overall survival and time to next treatment when receiving second-line PARP maintenance compared with active surveillance.

Investigators believe that neoadjuvant chemotherapy may play a role in mandibular prevention in patients with oral cavity cancer.

Patients with ovarian clear cell cancer did not seem to derive additional benefit after undergoing retroperitoneal lymphadenectomy.